Liraglutide

• Risk Factors Affect Weight Loss Outcomes After Treatment.
  Unknown Phase COMPLETED E-DA Hospital
• Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
  Unknown Phase COMPLETED Novo Nordisk A/S
• Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
  Unknown Phase ACTIVE_NOT_RECRUITING University Hospital Birmingham
• In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
  Unknown Phase COMPLETED Novo Nordisk A/S
• Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
  Unknown Phase COMPLETED Novo Nordisk A/S

Showing 5 of 44 trials.

• A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.
  Neuron unknown
• Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.
  Eur Heart J unknown
• Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
  Diabetes Care unknown
• Circadian rhythm-aligned time-restricted feeding prevents ovariectomy-induced fat gain, insulin resistance, and osteosarcopenia in rats.
  J Nutr unknown
• Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.
  Ann Am Thorac Soc unknown

Showing 5 of 12 papers by citation count.

FDA Data

Frequently Asked Questions